0001209191-18-001200.txt : 20180103 0001209191-18-001200.hdr.sgml : 20180103 20180103175033 ACCESSION NUMBER: 0001209191-18-001200 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180103 FILED AS OF DATE: 20180103 DATE AS OF CHANGE: 20180103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Firuta Paul E CENTRAL INDEX KEY: 0001602727 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36294 FILM NUMBER: 18507100 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE, THIRD FLOOR CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: uniQure N.V. CENTRAL INDEX KEY: 0001590560 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP BUSINESS PHONE: 1-339-970-7000 MAIL ADDRESS: STREET 1: PAASHEUVELWEG 25A CITY: AMSTERDAM STATE: P7 ZIP: 1105 BP FORMER COMPANY: FORMER CONFORMED NAME: uniQure B.V. DATE OF NAME CHANGE: 20131030 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-03 0 0001590560 uniQure N.V. QURE 0001602727 Firuta Paul E C/O UNIQURE N.V. PAASHEUVELWEG 25A AMSTERDAM P7 P7 1105BP NETHERLANDS 0 1 0 0 Chief Commercial Officer Ordinary Shares 2018-01-03 4 S 0 5864 20.1276 D 85251 D As required by the relevant Restricted Share Unit Agreement, the reporting person sold the ordinary shares and remitted the proceeds therefrom to the issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.66 to $20.47, inclusive. The reporting person undertakes to provide uniQure N.V., any security holder of uniQure N.V. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price ranges set forth in this footnote. Consists of (i) 11,636 ordinary shares, (ii) 56,115 performance share units that vest in full on January 27, 2020 and (iii) 17,500 restricted stock units previously disclosed by the reporting person on Table II, that vest in full on December 31, 2018. /s/ Christian Klemt, Attorney-In-Fact 2018-01-03